Tag: Viaskin® Peanut
DBV Withdraws FDA Application for Viaskin Peanut with Plan to Resubmit
The company believes the additional information needed to support this filing is available without further clinical studies.
Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for...
An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
DBV Applies for FDA License to Sell Viaskin Peanut Patch Therapy
"This submission represents a significant step forward for those families living with peanut allergy."
Viaskin Peanut Completes Phase III Part A Study of Toddlers With...
Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
Positive Safety Results Reported for Viaskin Peanut Phase III Trial
The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.
Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA...
The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.
DBV Completes Phase III Study of Peanut Patch
The phase III trial was designed to assess the safety and routine clinical use of Viaskin Peanut.
Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of...
The study received higher-than-expected patient demand.
Study: Peanut Immunotherapy Significantly Reduces Risks Due to Cross-Contact in Common...
The study model used common packaged foods such as cookies, ice cream, and doughnuts as references.
Viaskin Peanut Patch: Lasting Response After Three Years
Pediatric patients responded with a favorable safety profile and no serious adverse effects.
